This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Conflict of interest in academic research
Go to paperABSTRACT: The potential for conflict of interest in research can occur whenever a faculty member’s …
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
A new season for biotechnology in Europe
Go to paperABSTRACT: Comments on the status of the biotechnology industry in Europe as of March 2002. Research s…
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Welcome to Biotech Nation
Go to paperABSTRACT: Welcome to Biotech NationMoira A. Gunn, PhDAMACOM, New York, NY;ISBN: 978 0814409237; 2007; 258pp; hardbac…
Gerry Langeler, author of The Success Matrix and Managing Director with OVP Venture Partners recently spoke at a breakfast event and was kind
This is a guest post from Steve McLaughlin, Managing Partner and Founder of US BioSearch. Do you have a response to
Key Elements of Succession Planning In Bioscience Read Post »
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The legal and ethical considerations relating to the supply and use of human tissue for biomedical research: A UK perpective
Go to paperABSTRACT: Alder H…
I will be presenting at Bioinnovation 2014 in Gdansk, Poland on October 20-21st. My talk will cover entrepreneurship and business
This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Embryo and stem cell research: Views from the USA
Go to paperABSTRACT: Presents a study that examined the history, ethical debates and religious views r…
Embryo and stem cell research: Views from the USA Read Post »
In this article, we look at how patent filings in three key areas of genome-related research indicate the direction of private and public research in sequencing technology, personalised medicine and synthetic biology. Patent landscaping allows for anal…
Trends in patent filings depict a decade of research into the genome-based technologies Read Post »
The Biotechnology Industry Organization (BIO) held its 2014 Annual Convention at the San Diego Convention Center, CA (June 23-26, 2014). This event was attended by more than 15,660 industry leaders that included 2,500 Chief Executive Officers (CEOs), several U.S. Governors, and representatives from 50 states and 70 countries. The BIO Exhibition saw presence of over 1,800 exhibitors with 55 state and international pavilions. Additional features of the Convention comprised 192 company presentations, 800 speakers and 160 sessions in 9 specialty forums and 8 educational tracks and 29,000+ one-on-one partnering meetings between 3,100+ companies. Keynote speakers featured Sir Richard Branson and Former Secretary of State Hillary Rodham Clinton.
Advances in drug development & approvals landscape, and industry partnerships Read Post »